Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

Journal of Viral Hepatitis

Volumn 19, Issue 9, 2012, Pages 623-634

  Pianko, S ^a   Zeuzem, S ^b   Chuang, W L ^c   Foster, G R ^d   Sarin, S K ^e   Flisiak, R ^f   Lee, C M ^g   Andreone, P ^h   Piratvisuth, T ⁱ   Shah, S ^j   Sood, A ^k   George, J ^l   Gould, M ^m   Komolmit, P ⁿ   Thongsawat, S ^o   Tanwandee, T ^p   Rasenack, J ^q   Li, Y ^r   Pang, M ^s   Yin, Y ^s   Feutren, G ^s   Jacobson, I M ^t   more..

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e G B PANT HOSPITAL   (India)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^j JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^k DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^l UNIVERSITY OF SYDNEY   (Australia)

^m Toronto Digestive Disease   (Canada)

ⁿ KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^o Faculty of Medicine Chiang Mai University   (Thailand)

^p MAHIDOL UNIVERSITY   (Thailand)

^q UNIVERSITY OF FREIBURG   (Germany)

^r NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^s NOVARTIS PHARMA AG   (Switzerland)

^t WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

albinterferon alfa 2b; hepatitis C virus; interferon; sustained virologic response

Indexed keywords

ALBINTERFERON ALPHA2B; HEMOGLOBIN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; AUSTRALIA; CANADA; CONTROLLED STUDY; COUGHING; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GENOTYPE; GERMANY; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; INDIA; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLAND; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPAIN; TAIWAN; THAILAND; UNITED KINGDOM;

ADULT; ALBUMINS; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84864665171     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01586.x     Document Type: Article

References (21)

1. Lavanchy D,. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl. 1): 74-81.
2. Te HS, Jensen DM,. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1-21.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
4. Subramanian GM, Fiscella M, Lamousé-Smith A, Zeuzem S, McHutchison JG,. Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25: 1411-1419. (Pubitemid 350233139)
5. Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44: 671-678.
6. Nelson DR, Benhamou Y, Chuang WL, et al. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010; 139: 1267-1276.
7. Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010; 139: 1257-1266.
8. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
9. Division of Microbiology and Infectious Diseases Adult Toxicity Tables. Available at: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/ pages/toxtables.aspx. (accessed 28 December 2010).
10. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
11. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48: 407-417.
12. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-433. (Pubitemid 41111423)
13. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S,. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 69-75.
14. Roberts SK, Weltman MD, Crawford DH, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009; 5: 1045-1055.
15. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
16. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
17. Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-754.
18. Scherzer TM, Hofer H, Staettermayer AF, et al. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2011; 54: 866-871.
19. Slavenburg S, Heijdra YF, Drenth JP,. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci 2010; 55: 579-585.
20. Arase Y, Suzuki F, Suzuki Y, et al. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J Gastroenterol 2008; 14: 5880-5886.
21. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.